Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

Panelists discuss how the DESTINY-PanTumor 02 trial demonstrated significant efficacy of trastuzumab deruxtecan in HER2-amplified biliary tract cancer (BTC), with promising response rates and durability that support its use as a treatment option for these patients.

EP: 1.Guiding Patients Through Advanced BTC Prognosis and Expectations

EP: 2.The Importance of Early Biomarker Testing in Managing Advanced BTC

EP: 3.Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP: 4.Expert Insights: Challenges With ctDNA Testing in BTC

EP: 5.Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP: 6.Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP: 7.Understanding HER2 Testing in BTC: Detection and Clinical Approaches

Now Viewing

EP: 8.Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

Video content above is prompted by the following:

• We have several currently available therapies for those with HER2-amplified and HER2-positive tumors. What are your main takeaways from the DESTINY-PanTumor 02 trial with trastuzumab deruxtecan?

Related Videos